enGene Holdings Inc. (NASDAQ:ENGNW) Sees Large Decline in Short Interest

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 1,000 shares, a decline of 60.0% from the October 15th total of 2,500 shares. Based on an average trading volume of 3,300 shares, the short-interest ratio is presently 0.3 days.

enGene Stock Performance

ENGNW traded up $0.10 during trading on Thursday, reaching $1.45. 146 shares of the company were exchanged, compared to its average volume of 19,520. The company’s 50-day moving average is $1.69 and its two-hundred day moving average is $1.81. enGene has a 12-month low of $0.40 and a 12-month high of $6.50.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.